Pharmacogenomic analysis of TGFB1 towards uterine leiomyomas
Author(s):
Sunitha VR, VL Pushpa, Divya V and KB Manoj
Abstract:
Uterine leiomyomas commonly called fibroids are benign monoclonal tumors of uterine smooth muscle found in women of reproductive age. Variations in TGFB1 gene hold a significant role in enhancing the growth of Uterine leiomyoma. The pharmacogenetic and pharmacogenomic analysis of the mutation have been carried out to characterize the individual variation in the proneness of the disease. The SNPs rs146182311, rs148552731, rs1800471, rs104894722 and rs111033611 have been identified as the genetic signatures behind proneness of the disease. During epigenetic analysis, the attributes, ‘Evolutionary history and Transcriptome’ have been pointed out as the major variant responsible for DNA methylation and further mutation. It has been found that the chromosome region, 41341952- 41352971 stands out as the most sensitive positions corresponding to population wise variation. Moreover, the European, South Asian and African populations have been identified as most prone to the mutation. The pharmacogenomic analysis reveals the involvement of TGFBR1, TGFBR2, DCN, SMAD3 and SMAD2 genes for the tumor growth.
How to cite this article:
Sunitha VR, VL Pushpa, Divya V, KB Manoj. Pharmacogenomic analysis of TGFB1 towards uterine leiomyomas. Pharma Innovation 2024;13(11):22-24.